KR20050095166A - Composition for reducing weight, preventing fatness and treating fatness by comprising leconostoc mensenteroids as an effect gradient - Google Patents
Composition for reducing weight, preventing fatness and treating fatness by comprising leconostoc mensenteroids as an effect gradient Download PDFInfo
- Publication number
- KR20050095166A KR20050095166A KR1020040020375A KR20040020375A KR20050095166A KR 20050095166 A KR20050095166 A KR 20050095166A KR 1020040020375 A KR1020040020375 A KR 1020040020375A KR 20040020375 A KR20040020375 A KR 20040020375A KR 20050095166 A KR20050095166 A KR 20050095166A
- Authority
- KR
- South Korea
- Prior art keywords
- mensenteroids
- leuconostoc
- weight
- composition
- fatness
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D21/00—Nestable, stackable or joinable containers; Containers of variable capacity
- B65D21/02—Containers specially shaped, or provided with fittings or attachments, to facilitate nesting, stacking, or joining together
- B65D21/0209—Containers specially shaped, or provided with fittings or attachments, to facilitate nesting, stacking, or joining together stackable or joined together one-upon-the-other in the upright or upside-down position
- B65D21/0217—Containers with a closure presenting stacking elements
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/38—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents with thermal insulation
- B65D81/3865—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents with thermal insulation drinking cups or like containers
- B65D81/3869—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents with thermal insulation drinking cups or like containers formed with double walls, i.e. hollow
Landscapes
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)를 유효성분으로 함유하는 체중 감량 및 비만 예방 및 치료용 조성물에 관한 것으로, 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)를 유효성분으로 함유하는 체중 감량 및 비만 예방 및 치료용 조성물을 제조한 다음 금속이온 Ca2+의 존재하에 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)가 가지는 단당류 감소효과를 조사하고 류코노스톡 멘센테로이드의 단당류 종류에 따른 올리고당 생성효과를 조사한 후 류코노스톡 멘센테로이드의 단당류 농도에 따른 올리고당 생성효과를 조사함으로써 주 열량원인 탄수화물의 흡수율을 저하시켜 체중감량, 비만의 예방 및 치료효과를 가지는 뛰어난 효과가 있으므로 건강식품산업상 매우 유용한 발명인 것이다.The invention flow Pocono stock Mentioned Centennial Lloyd (Leuconostoc mensenteroids) the present invention relates to weight reduction and obesity prevention and treatment composition containing as an active ingredient, flow Pocono stock Mentioned Centennial Lloyd (Leuconostoc mensenteroids) weight loss, which contain as an active ingredient And preparing a composition for preventing and treating obesity and then investigating the monosaccharide reduction effect of Leuconostoc mensenteroids in the presence of metal ions Ca 2+ and producing oligosaccharides according to the types of monosaccharides After investigating the effects of oligosaccharides according to the monosaccharide concentrations of leukonostock mensenteroids, the absorption rate of carbohydrates, which is the main calorie source, is lowered, and thus the weight loss, obesity prevention and treatment effects are excellent. It is a useful invention.
Description
본 발명은 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)를 유효성분으로 함유하는 체중 감량 및 비만 예방 및 치료용 조성물에 관한 것으로, 체중 다이어트 효과를 갖는 생균제인 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)의 첨가에 의한 체중 감량 및 비만의 예방과 치료를 위한 기능성 건강보조식품 조성물에 관한 것이다.The present invention relates to a composition for preventing and treating weight loss and obesity containing Leuconostoc mensenteroids as an active ingredient, the probiotics of Leuconostoc mensenteroids ( Leuconostoc mensenteroids ) having a weight diet effect It relates to a functional dietary supplement composition for the prevention and treatment of weight loss and obesity by addition.
대한민국 특허공개번호 제 2003-0075067호에서는 비만을 해결하기 위한 식이요법 및 부작용이 적은 천연물질로서의 귤 진피층의 섬유소 사용방법이 공지된바 있다.In Korean Patent Publication No. 2003-0075067, there is a known dietary method for solving obesity and a method of using fibrin of the tangerine dermis layer as a natural substance with less side effects.
또한, 대한민국 특허공개번호 제 2003-0080345호에서는 고추에서 분리한 캡사이신에 의한 체내 산소소비량의 증가가 베타-아드레너직 블록(β-adrenergic blocker)에 의해 다이어트 효과가 있다고 공지하였다.In addition, Korean Patent Publication No. 2003-0080345 discloses that an increase in the body oxygen consumption by capsaicin isolated from red pepper has a diet effect by the beta-adrenergic blocker.
더불어, 대한민국 특허공개번호 제 2003-0083347호에서는 생식 및 선식 조성물이 생체기능 활성화 및 다이어트에 효과적이라는 공지가 있으며, 대한민국 특허공개번호 제 2000-49633호에는 자연선식과 그 제조방법이 개시되어 있다.In addition, Korean Patent Publication No. 2003-0083347 discloses that the reproductive and dietary composition is effective for activating a biological function and diet, and Korean Patent Publication No. 2000-49633 discloses a natural wire and a manufacturing method thereof.
즉, 종래의 건강보조식품으로 체중 다이어트 효과를 나타내는 제품들은 거의가 식이섬유 또는 기타 물질의 첨가로 영양원을 직접 조정 하거나 또는 난소화성 성분을 섭취하는 방법이 주종을 이루었다. 하지만 이는 식이섭취량 조절을 같이 하여야 하며, 이에 따라 식사량을 조정해주는 간접적인 방법이 병행되어야 한다. 그러나 과거 대부분의 체중조절 식이요법은 현대인의 식생활습관이나 잦은 외식으로 인하여 바쁜 현대인들에게는 지키기 어려운 일이다.In other words, the products that exhibit the weight diet effect as a conventional dietary supplement mostly do the diet or direct ingestion of indigestible ingredients by the addition of dietary fiber or other substances. However, this should be accompanied by dietary intake adjustments, and therefore indirect methods of adjusting the amount of meals should be combined. However, most weight-control diets in the past are difficult to keep up with for busy modern people due to their eating habits and frequent eating out.
이에 본 발명은 상기와 같은 문제점을 해결하고자 안출된 것으로, 식이섭취량은 가급적 유지하면서, 체중 다이어트 및 비만의 예방과 치료를 위한 건강보조식품으로 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)를 유효성분으로 하는 조성물을 제공하는데 그 목적이 있다.Accordingly, the present invention has been made to solve the above problems, while maintaining the dietary intake as possible, as a dietary supplement for the prevention and treatment of weight diet and obesity as Leuconostoc mensenteroids ( Leuconostoc mensenteroids ) as an active ingredient It is an object to provide a composition to.
본 발명의 상기 목적은 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)를 유효성분으로 함유하는 식품 조성물을 제조한 다음 금속이온 Ca2+의 존재하에 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)가 가지는 단당류 감소효과를 조사하고 류코노스톡 멘센테로이드의 단당류 종류에 따른 올리고당 생성효과를 조사한 후 류코노스톡 멘센테로이드의 단당류 농도에 따른 올리고당 생성효과를 조사함으로써 달성하였다.The object of the present invention is to prepare a food composition containing Leuconostoc mensenteroids ( Leuconostoc mensenteroids ) as an active ingredient, and then reduce the monosaccharides of Leuconostoc mensenteroids ( Leuconostoc mensenteroids ) in the presence of metal ions Ca 2+ After investigating the effects and investigating the oligosaccharide production effect according to the monosaccharide type of leuconosstock mencenteroid, it was achieved by investigating the oligosaccharide production effect according to the monosaccharide concentration of the leuconosstock mencenteroid.
이하 본 발명의 구성을 설명한다.Hereinafter, the configuration of the present invention.
본 발명은 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)를 유효성분으로 함유하는 식품 조성물을 제조하는 단계; 금속이온 Ca2+의 존재하에 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)가 가지는 단당류 감소효과를 조사하는 단계; 류코노스톡 멘센테로이드의 단당류 종류에 따른 올리고당 생성효과를 조사하는 단계; 류코노스톡 멘센테로이드의 단당류 농도에 따른 올리고당 생성효과를 조사하는 단계로 구성된다.The present invention comprises the steps of preparing a food composition containing Leuconostoc mensenteroids ( Leuconostoc mensenteroids ) as an active ingredient; Investigating the monosaccharide reduction effect of Leuconostoc mensenteroids in the presence of metal ions Ca 2+ ; Investigating the oligosaccharide production effect according to the monosaccharide type of leuconosstock mencenteroid; Comprising the step of investigating the oligosaccharide production effect according to the monosaccharide concentration of the leuconosstock men centeroid.
본 발명은 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)(기탁번호: KCCM 11324)를 유효성분으로 함유하는 것을 특징으로 하는 체중 감량 및 비만 예방 및 치료용 조성물을 제공한다.The present invention provides a composition for preventing and treating weight loss and obesity, characterized by containing Leuconostoc mensenteroids (Accession Number: KCCM 11324) as an active ingredient.
본 발명에서 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)는 1×105~1×1011생균수/g인 것이 바람직하다.In the present invention, Leuconostoc mensenteroids ( Leuconostoc mensenteroids ) is preferably 1 × 10 5 ~ 1 × 10 11 viable bacteria / g.
본 발명의 체중 감량 및 비만 예방 및 치료용 조성물은 전체 중량 100중량부을 기준으로 하여 효모 20~30 중량부, 치커리 화이바 50~70 중량부, 패각칼슘 2~3 중량부, 캄보지아 3~5 중량부를 추가로 포함할 수 있다. The weight loss and obesity prevention and treatment composition of the present invention is based on 100 parts by weight of the yeast 20 to 30 parts by weight, 50 to 70 parts by weight of chicory fiber, 2 to 3 parts by weight of calcium calcium, 3 to 5 parts by weight of cambogia It may further comprise.
이하, 본 발명에 대해 더욱 상세히 설명한다. Hereinafter, the present invention will be described in more detail.
본 발명은 장내에서 섭취된 단당류를 대사과정을 통해서 난분해성 올리고당으로 합성하는 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)를 피막 처리하여 사용한다. 이 생균은 유산균의 일종으로 젖산을 생성하며 정장작용을 하여 장내의 소화율을 증대시키고 항생물질을 생산함으로써 병원성균이나 식중독균의 성장을 저해하는 효과가 있다.The present invention is used to coat the leuconostoc mensenteroids ( Leuconostoc mensenteroids ) for synthesizing monosaccharides ingested in the intestine into hardly degradable oligosaccharides. This live bacterium is a kind of lactic acid bacterium that produces lactic acid and increases the digestibility of the intestine by intestinal action and produces antibiotics, thereby inhibiting the growth of pathogenic bacteria and food poisoning bacteria.
본 발명에서는 위와 같은 장점이 있는 류코노스톡 멘센테로이드(Leuconostoc mensenteroids) 1×105~1×1011생균수/g을 함유하는 것을 특징으로 체중감량, 비만 예방 및 치료용 조성물을 제공한다. 이때, 생균수가 1×105 미만인 경우에는 유의적인 예방 및 치료효과를 달성할 수가 없으며, 1×1011초과인 경우에는 1×1011에 비해 유의적인 효과의 증가가 없다.The present invention provides a composition for weight loss, prevention and treatment of obesity, characterized by containing 1 × 10 5 ~ 1 × 10 11 viable cell number / g of Leuconostoc mensenteroids ( Leuconostoc mensenteroids ) having the above advantages. At this time, the viable cell number of 1 × 10 5 less than cases not possible to achieve a significant preventive and therapeutic effect, in the case of 1 × 10 11 than there is no increase in the significant effect relative to 1 × 10 11.
한편, 본 발명에서는 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)의 생육 시에 발행할 수 있는 문제점을 해결하고, 강장 효과를 보다 현저히 증가시키기 위하여, 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)를 1×105~1×1011생균수/g 함유하는 것을 특징으로 체중감량, 비만 예방 및 치료용 조성물에 있어, 전체 중량 100 중량부를 기준으로 하여 건조효모 20~30 중량부, 치커리 화이바 50~70 중량부, 패각칼슘 2~3 중량부, 캄보지아 3~5 중량부를 추가적으로 포함하는 체중 감량, 비만 예방 및 치료용 조성물을 제공할 수 있다.On the other hand, in the present invention, in order to solve the problems that can be issued during the growth of Leuconostoc mensenteroids ( Leuconostoc mensenteroids ), and to increase the tonic effect more significantly, Leuconostoc mensenteroids 1 × In the composition for weight loss, obesity prevention and treatment, containing 10 5 ~ 1 × 10 11 viable bacteria / g, 20 ~ 30 parts by weight of dry yeast, 50 ~ 70 weight of chicory fiber based on 100 parts by weight of the total Part, may provide a composition for weight loss, obesity prevention and treatment comprising 2 to 3 parts by weight of shell calcium, 3 to 5 parts by weight of cambogia.
이때 첨가되는 건조효모는 제약원료로 사용하거나 맥주효모의 우수한 단백질 성분으로 인해 가축사료용으로 이용되어 왔으며, 본 발명에서는 인체 대사활성의 증진뿐만 아니라 코노스톡 멘센테로이드가 장내에서 성장 또는 대사하는데 비타민 및 아미노산을 공급하는 역할을 한다. 그 첨가량이 70 중량부를 초과하는 경우에는 과도한 핵산의 함량으로 인하여 통풍 환자에게 역효과를 일으키는 문제가 발생하게 된다.At this time, the added dry yeast has been used as a pharmaceutical raw material or a livestock feed due to the excellent protein components of beer yeast, in the present invention, as well as enhancing the metabolic activity of the human body as well as the growth or metabolism of the conostock mensentoid vitamins and It serves to supply amino acids. If the amount exceeds 70 parts by weight, the problem of adverse effects on gout patients occurs due to the excessive content of nucleic acids.
치커리 화이바는 식이섬유의 공급으로 장내 정장작용 및 숙변제거에 이용되며, 그 첨가량이 50 중량부 미만일 경우에는 특히 효과를 기대할수 없고, 70 중량부 이상이면 미네랄 등의 유효성분의 흡착이 우려된다.Chicory fiber is used for intestinal intestinal function and stool removal by supplying dietary fiber, especially when the added amount is less than 50 parts by weight, the effect can not be expected, if more than 70 parts by weight of the adsorption of active ingredients such as minerals.
캄보지아는 지방의 분해를 촉진하여 역시 체중 감량에 효과가 있으나, 그 첨가량이 3 중량부 미만일 경우에는 별다른 효과가 없으며, 5 중량부 이상일 경우에는 부작용이 유발되어 법적인 규제치에 저촉된다.Cambogia promotes the breakdown of fat, which is also effective in weight loss, but when the added amount is less than 3 parts by weight, there is no effect, and when it is 5 parts by weight or more, it causes side effects and violates the legal regulations.
상기 정장 기능성을 지닌 류코노스톡 멘센테로이드를 유효성분으로 하는 조성물 또는 여기에 건조효모 및 치커리 화이바등을 일정한 비율로 혼합한 조성물은 장질환이 있는 환자에게 제공하였을 경우에 정장기능이 유의적으로 증가되는 효과를 볼 수 있으며, 특히 장질환 중 변비 또는 설사환자에게 투여할 경우, 변비가 해소되거나 설사가 중지되는 효과를 얻을 수 있다. The composition comprising the leukonostock mensenteroid having the formal function as an active ingredient or a composition in which dry yeast and chicory fiber are mixed at a constant ratio is significantly changed when the formal function is provided to a patient with bowel disease. Increased effects can be seen, especially when administered to patients with constipation or diarrhea during bowel disease, constipation can be resolved or diarrhea can be stopped.
한편, 상기 조성물은 제조 후, 정제 또는 캡슐 형태로 제조하여 판매될 수 있다. Meanwhile, the composition may be manufactured and sold in the form of a tablet or capsule after manufacture.
이하, 본 발명의 구성을 실시 예를 들어 상세히 설명하지만, 본 발명의 권리 범위가 하기 실시예에만 한정되는 것은 아니다. Hereinafter, the configuration of the present invention will be described in detail with reference to Examples, but the scope of the present invention is not limited only to the following Examples.
실시예 1 : 류코노스톡 멘센테로이드(Example 1 Leukonostock Mensenteroid ( Leuconostoc mensenteroidsLeuconostoc mensenteroids )를 유효성분으로 함유하는 식품 조성물의 제조Preparation of a food composition containing) as an active ingredient
1×105~1×1011생균수/g의 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)(기탁번호: KCCM 11324) 2g, 건조효모 20.0g, 치커리 화이바 70g, 패각칼슘 3g, 가르지니아 캄보지아 5g을 칭량하고 혼합기로 혼합하여 상기 생균수를 포함하는 조성물을 제조하였다. 상기 혼합된 조성물은 분말형태로 1포당 5~10g씩 1회용 파우치(pouch)로 포장하였다. Leuconostoc mensenteroids (Accession No .: KCCM 11324) with 1 × 10 5 to 1 × 10 11 viable cell count / g, 2 g of dry yeast, 70 g of chicory fiber, 70 g of shell calcium, 5 g of Garcinia cambogia Was weighed and mixed with a mixer to prepare a composition comprising the viable bacteria. The mixed composition was packaged in a disposable pouch (5 ~ 10g per package) in powder form.
이때 건조효모는 기린 브레웨리(KIRIN BREWERY)사에서 제조되어 (주)케이엘 라인(KL Line)으로부터 수입된 브레웨어의 건조 효모 A(Brewer's dried yeast A)를, 치커리 화이바는 사하콜 푸드(Sahachol Food)사에서 제조되어 (주)케이엘 라인(KL Line)으로부터 수입된 DC2 20011017 곤약 가루(Konjac Flour)를, 패각칼슘은 (주)후드라인에서 제조 및 공급받은 제품을, 가르지니아 캄보지아는 인드프라그 리미티드(Indfrag Limited)사에서 제조되어 (주)케이엘 라인(KL Line)으로부터 수입된 GCP 03070 가르시아나 캄보지아 추출물(Garcinia cambogia extract)을 사용하였다. At this time, dry yeast is brewer's dried yeast A manufactured by KIRIN BREWERY and imported from KL Line, and chicory fiber is Sahachol Food. DC2 20011017 Konjac Flour manufactured by Co., Ltd. and imported from KL Line. Shell calcium is manufactured and supplied by Hoodline Co., Ltd. GCP 03070 Garciana cambogia extract manufactured by (Indfrag Limited) and imported from KL Line Co., Ltd. was used.
실험예 1: 금속이온 CaExperimental Example 1 Metal Ion Ca 2+2+ 의 존재하에 류코노스톡 멘센테로이드(In the presence of leukonostock mensenteroids ( Leuconostoc mensenteroidsLeuconostoc mensenteroids )가 가지는 단당류 감소효과 조사Investigation of monosaccharide reduction effect
류코노스톡 멘센테로이드(Leuconostoc mensenteroids)는 일부 금속이온의 존재하에 식이로 공급되어진 단당류를 다시 난분해성 올리고당으로 합성하면서 더욱 많은 효능을 갖는다. 이를 확인하기 위하여 CaCl2를 정지기의 배양액에 10~55mMol을 혼합하여 37℃에서 4시간 정치한후 올리고당의 형성에 의한 점도의 증가를 오스왈드점도계로 측정하였다(도 1). 칼슘이온을 적정량 포함하는 조제배지에 류코노스톡 멘센테로이드를 배양하여 균을 접종하지 않은 군과 균을 접종한 군의 점도차의 증감추세를 오스왈드 점도계를 이용하여 측정하였다. Leuconostoc mensenteroids have more efficacy in synthesizing monosaccharides supplied in the diet again in the presence of some metal ions into hardly degradable oligosaccharides. In order to confirm this, CaCl 2 was mixed with 10 ~ 55mMol in the culture medium of the stationary phase and allowed to stand at 37 ° C for 4 hours, and the increase in viscosity due to the formation of oligosaccharides was measured by an Oswald viscometer (FIG. 1). The increase and decrease of the viscosity difference between the group inoculated with the bacterium and the group inoculated with the bacterium by incubating the leuconosstock mensenteroid in a preparation medium containing an appropriate amount of calcium ions was measured using an Oswald viscometer.
이 때, 점도 증가(Viscosity Increasing)는 균주를 접종하지 않은 배지와 접종한 배지의 점도를 각각 오스왈드 점도계로 측정한 후 각 시간대의 점도값의 차이를 나타낸 것이다.At this time, the viscosity increase (Viscosity Increasing) shows the difference between the viscosity value of each time period after measuring the viscosity of the inoculated medium and the inoculated medium with the Oswald viscometer, respectively.
그 결과 배양액중 Ca2+이온이 30mM수준일 경우에 가장 큰 점도의 증가를 보였다. 따라서, 본 발명의 조성물 함량중 패각칼슘의 첨가수준을 2~3 중량부로 설정하였다.As a result, the Ca 2+ ions in the culture medium showed the greatest increase in viscosity at the 30mM level. Therefore, the addition level of shell calcium in the composition content of the present invention was set to 2-3 parts by weight.
실험예 2: 류코노스톡 멘센테로이드의 단당류 종류에 따른 올리고당 생성효과 조사Experimental Example 2: Investigation of the oligosaccharide formation effect according to the monosaccharide type of leuconosstock mensenteroid
실험예 1에서와 같이 류코노스톡 멘센테로이드 균주는 금속이온의 존재하에 올리고당을 생성한다. 그리고 이때 체내에서 사용할 것으로 생각되어지는 대표적인 단당류로 글루코스(glucose)와 이당류의 수크로스(sucrose) 각각을 식품에서 배양액에 첨가하여 각 당류의 차이에 따라 올리고당의 생성효율을 조사하였다(표 1).As in Experimental Example 1, the leukonostock mensenteroid strain produces oligosaccharides in the presence of metal ions. At this time, glucose and disaccharide sucrose were added to the culture medium as representative monosaccharides considered to be used in the body, and the production efficiency of oligosaccharides was investigated according to the difference of each sugar (Table 1).
상기 결과에 따르면 류코노스톡 멘센테로이드는 수크로스와 글루코스중에서는 글루코스를 이용한 덱스트란 생성이 더 많았으나 수크로스를 이용한 것도 적지 않은 수치를 나타내어 단당류를 이용하여 덱스트란을 생성한 것임이 밝혀졌다. According to the results, it was found that leuconosstock mensenteroids produced more dextran using glucose among sucrose and glucose, but also produced dextran using monosaccharides. .
실험예 3: 류코노스톡 멘센테로이드의 단당류 농도에 따른 올리고당 생성효과 조사Experimental Example 3: Investigation of the oligosaccharide formation effect according to the monosaccharide concentration of the leukonostock mensenteroid
단당류의 농도를 설정하면 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)의 체중 다이어트 효과를 명확히 할 수 있다. 체온인 37℃에서 수크로스를 농도별로 첨가하여 다당류의 형성을 조사하였다(도 2). 점도의 측정 방법은 실험예 1과 동일하게 하였다.By setting the concentration of monosaccharides, it is possible to clarify the weight diet effect of Leuconostoc mensenteroids . Sucrose was added at various temperatures at 37 ° C. to investigate the formation of polysaccharides (FIG. 2). The measurement method of the viscosity was the same as that of Experimental example 1.
그 결과, 저 농도의 단당류함유 배양액에서는 효과가 미미하였으나, 10mM 수준을 넘어서면서부터 급격한 증가추세를 보임을 알 수 있었다. 그러나, 50mM에 가까울수록 증가추세가 둔해지어 더 이상의 효과를 기대하기는 어려운 것을 알 수 있었다. As a result, it was found that the effect was low in the monosaccharide-containing medium, but showed a sharp increase from the 10mM level. However, it was found that the closer to 50mM, the slower the growth trend, and it is difficult to expect more effects.
이상 상기에서 살펴본 바와 같이 본 발명 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)를 유효성분으로 함유하는 체중 감량 및 비만 예방 및 치료용 조성물은 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)를 유효성분으로 함유하는 조성물을 제조한 다음 금속이온 Ca2+의 존재하에 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)가 가지는 단당류 감소효과를 조사하고 류코노스톡 멘센테로이드의 단당류 종류에 따른 올리고당 생성효과를 조사한 후 류코노스톡 멘센테로이드의 단당류 농도에 따른 올리고당 생성효과를 조사함으로써 주 열량원인 탄수화물의 흡수율을 저하시켜 체중감량, 비만의 예방 및 치료효과를 가지는 뛰어난 효과가 있으므로 건강식품산업상 매우 유용한 발명인 것이다.As described above, the composition for weight loss and obesity prevention and treatment containing Leuconostoc mensenteroids ( Leuconostoc mensenteroids ) as an active ingredient of the present invention contains Leuconostoc mensenteroids ( Leuconostoc mensenteroids ) as an active ingredient. After preparing the composition, the effect of reducing monosaccharides of Leuconostoc mensenteroids in the presence of metal ions Ca 2+ and the effect of oligosaccharide formation according to the types of monosaccharides of leuconosstock mensenteroids were investigated. By investigating the oligosaccharide formation effect of the monosaccharide concentration of stock menenteroids, it is a very useful invention in the health food industry because it has an excellent effect of reducing the absorption rate of carbohydrates, which is the main calorie source, and having a weight loss prevention and treatment effect.
도 1은 오스왈드점도계를 이용한 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)의 금속이온하에서 증가되는 점도의 변화를 나타내는 그래프이다.FIG. 1 is a graph showing the change of viscosity increased under metal ion of Leuconostoc mensenteroids using an Oswald viscometer.
도 2는 오스왈드점도계를 이용한 류코노스톡 멘센테로이드(Leuconostoc mensenteroids)의 단당류 농도에 따른 점도의 변화를 나타내는 그래프이다.Figure 2 is a graph showing the change in viscosity according to the monosaccharide concentration of Leuconostoc mensenteroids ( Leuconostoc mensenteroids ) using the Oswald viscometer.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020040020375A KR20050095166A (en) | 2004-03-25 | 2004-03-25 | Composition for reducing weight, preventing fatness and treating fatness by comprising leconostoc mensenteroids as an effect gradient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020040020375A KR20050095166A (en) | 2004-03-25 | 2004-03-25 | Composition for reducing weight, preventing fatness and treating fatness by comprising leconostoc mensenteroids as an effect gradient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20050095166A true KR20050095166A (en) | 2005-09-29 |
Family
ID=37275715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020040020375A KR20050095166A (en) | 2004-03-25 | 2004-03-25 | Composition for reducing weight, preventing fatness and treating fatness by comprising leconostoc mensenteroids as an effect gradient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20050095166A (en) |
-
2004
- 2004-03-25 KR KR1020040020375A patent/KR20050095166A/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2255815B1 (en) | Nutritional composition | |
| EP3065569B1 (en) | Composition | |
| DE502007010071C5 (en) | USE OF A MINERAL COMPOSITION AND, WHERE APPROPRIATE, ACETOGENIC AND / OR BUTYROGENIC BACTERIA TO AVOID OR REDUCE GAS FORMATION IN THE THICKNESS OF ANIMALS AND THEREFORE COMPLAINED ABDOMINAL | |
| CN106619743A (en) | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink | |
| RU2509477C1 (en) | New sweeteners compositions | |
| JP2003522822A (en) | Inulin products with improved nutrition | |
| KR20050057419A (en) | Novel use of carbohydrates and compositions | |
| CN111227261A (en) | Prebiotic composition and application thereof | |
| CN113974043A (en) | Prebiotics solid beverage and preparation method thereof | |
| JP5442243B2 (en) | Renal disorder inhibitor | |
| US20020018818A1 (en) | Sugar decomposition inhibitor, digestive enzyme activity inhibitor, insulin secretion controller, and healthy food and beverage | |
| KR20030070029A (en) | Remedies for diabetes | |
| JPH03151854A (en) | Composition for improving intestinal environment | |
| JP2004155727A (en) | Composition for ameliorating defecation | |
| CN110710660A (en) | Blood sugar lowering composition and dietary supplement containing bitter gourd powder | |
| KR100424660B1 (en) | Vitamin-enriched nutritional food composition comprising Bacillus polyfermenticus KCCM 10104 effectively for prevention of intestinal disorders | |
| KR20090030441A (en) | Food composition for reducing abdominal obesity containing dietary fiber and fructooligosaccharide | |
| KR20180053361A (en) | An inhibitor of blood glucose level elevation and an oral composition containing the same | |
| KR100620477B1 (en) | Use of D-tagatose as a Prebiotic Food Component | |
| KR20050095166A (en) | Composition for reducing weight, preventing fatness and treating fatness by comprising leconostoc mensenteroids as an effect gradient | |
| IT202000015268A1 (en) | VEGETABLE FIBER HYDROLYSATE AND ITS USES IN HUMAN AND ANIMAL NUTRITION | |
| JPH0995448A (en) | Increase in biotin concentration in blood and biotin-containing beverage or food product | |
| CN110089751A (en) | Intestines arrange health care product | |
| JP2001048794A (en) | Health food and medicinal composition which contain mixture of powder originated from leaf of mulberry and powder originated from oyster and is used for treating niddm | |
| KR20200130030A (en) | Methods for the manufacture of yogurt products with the effect of blood sugar control on diabetics and potential patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Withdrawal due to no request for examination |